ClinicaliQ Trial Snapshot
- Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis — Recruiting • Cardiology / Cardiovascular • NCT00315380.
- What is being tested: A longitudinal observational study collecting long-term clinical data on eosinophilic granulomatosis with polyangiitis (EGPA) to better understand disease progression, treatment responses, and patient outcomes in this rare systemic vasculitis affecting multiple organ systems.
- Patient eligibility overview: The trial enrolls patients with confirmed EGPA diagnosis who present with the classic triad of asthma, peripheral eosinophilia, and vasculitis; participants are followed over extended periods to capture real-world disease trajectory and management patterns.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
Eligibility Snapshot
- : Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study. Parent or guardian willing to provide informed consent, if applicable
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.